Below is a personalized chart featuring areas of interest to the individual reader and supplied daily by THE NEW YORK TIMES, for the public as well as subscribers. Note that the unit they use is cases/100,00 population, whereas THE TEXAS TRIBUNE and I generally use cases/10,000 population..
Below is a Photo from TODAY: THIS IS MY PERSONALIZED CHART. OF ALL THE PUBLICATIONS THAT I READ, THIS IS THE BEST: QUICK, CONCISE, PERTINENT, THROUGH. YOU DON’T HAVE TO READ THE EDITORIALS UNLESS YOU WISH TO.
Notice that Smith County is currently having troubles.
Sunday Special: One article, important. I summarized below. Mostly good news.
In addition to neutralizing antibodies, mRNA vaccines [PFIZER AND MODERNA] also induce virus-specific helper T cells and cytotoxic T cells that might help protect against infection…
“For right now, you’ll know that a line is crossed if you see people fully immunized with the vaccines [who], nonetheless, when infected with the variants, are being hospitalized…[The hope is that the vaccines will at least work well enough against the mutants to prevent serious disease and/or death]>
Novavax and Janssen conducted larger trials in South Africa than Oxford and AstraZeneca. Although both of their vaccines had lower efficacy rates in South Africa than in trials in other countries, vaccinated participants who received the Janssen vaccine were still less likely to require hospitalization for COVID-19 than those who received placebo shots…[Janssen not approved in USA yet}
The US Centers for Disease Control and Prevention advises that even after they’re fully vaccinated, people should continue to mask up and socially distance in public places, in part because they could still unknowingly become infected and, although asymptomatic, transmit SARS-CoV-2 to people who haven’t yet received their shots.
… COVID-19 [could] join influenza as an infectious disease for which annual vaccination [or yearly booster] is required … it isn’t yet known. Although they’re both RNA viruses, the backdrop is so different…We are in a pandemic. We didn’t have a vaccine. This [mRNA vaccines] is new technology.
Pfizer and BioNTech announced February 25 that they had begun evaluating the safety and immunogenicity of a third dose of their vaccine to see whether it would boost immunity to SARS-CoV-2 variants…
Modifying vaccines to target variants isn’t difficult. For example, with Pfizer-BioNTech’s and Moderna’s mRNA vaccines, “it’s very convenient, because, basically, all you do is change a computer program and the synthetic for the synthesizing portion of this and you can change the vaccine,” [The new technology works AND MASKS WORK WELL AGAINST THE MUTANTS)
LAST BUT NOT LEASED, DIRECT FROM NEW YORK CITY TODAY:
GIVE US YOUR FEEDBACK. CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.